

ASX/Media Release (Code: PRR)

23 January 2013

# QUARTERLY ACTIVITY REPORT For Quarter ending 31 December 2012

Prima BioMed Ltd (Prima) (ASX: PRR; NASDAQ: PBMD; ISIN: US7415482034) today released its Appendix 4C – Quarterly Report for the three month period ending 31 December 2012.

The cash balance at 31 December 2012 was A\$ 28.07 million. The majority of funds spent during the quarter are related to development activities of Prima's lead product  $CVac^{TM}$ .

Business highlights from the quarter:

- Transition of Ian Bangs as CFO and Company Secretary to Marc Voigt as CFO and Deanne Miller as Company Secretary.
- Positive interim CVac data from the ongoing CAN-003 trial.
- Positive interim immune monitoring data from ongoing CAN-003 trial.
- Annual General Meeting at 16<sup>th</sup> of Nov 2012.

For more details about these highlights and Prima's activities, please refer to Prima's announcements on the ASX website.

# Appendix 4C – 2<sup>nd</sup> Quarter

# **Quarterly Report**

# For Entities Admitted on the Basis of Commitments

Introduced 31/3/2000. Amended 30/9/2001

#### Name of Entity:

ABN:

Quarter Ended ("Current Quarter")

90 009 237 889

31 December 2012

## **Consolidated Statement of Cash Flows**

		Current Quarter	Year-to-Date
	Cash flows related to operating activities	\$A'000	\$A'000
1.1	Receipts from customers	-	3
1.2	Payments for		
	(a) staff costs	(941)	(2,121)
	(b) advertising and marketing	(79)	(155)
	(c) research and development	(3,510)	(6,589)
	(d) leased assets	-	-
	(e) other working capital	(974)	(1,772)
1.3	Dividends received	-	-
1.4	Interest and other items of a similar nature received	87	684
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes benefit	-	-
1.7	Other - grants received	48	48
	Net operating cash flows	(5,369)	(9,902)

<sup>+</sup> See chapter 19 for defined terms.

		Current Quarter \$A'000	Year-to-Date \$A'000
1.8	Net operating cash flows (carried forward)	(5,369)	(9,902)
Cash	flows related to investing activities		
1.9	Payment for acquisition of:  (a) businesses (item 5)  (b) equity investments	-	- -
	<ul><li>(c) intellectual property</li><li>(d) physical non-current assets</li><li>(e) other non-current assets</li></ul>	(4)	- (55) -
1.10	Proceeds from disposal of:  (a) businesses (item 5)  (b) equity investments	-	-
	<ul><li>(c) intellectual property</li><li>(d) physical non-current assets</li><li>(e) other non-current assets</li></ul>	-	- - -
1.11 1.12 1.13	Loans to other entities Loans repaid by other entities Other (provide details if material)	- - -	- - -
Net in	nvesting cash flows	(4)	(55)
1.14	Total operating and investing cash flows	(5,373)	(9,957)
Cash	flows related to financing activities		
1.15 1.16 1.17 1.18	Proceeds from issues of shares, options, etc. Transfer of shares Proceeds from borrowings net finance costs Repayment of borrowings	- - -	- - -
1.19 1.20	Dividends paid Other - capital raising costs	-	-
Net fi	nancing cash flows	-	-
Net in	ncrease (decrease) in cash held	(5,373)	(9,957)
1.21	Cash at beginning of quarter/year to date	33,466	38,037
1.22	Exchange rate adjustments to item 1.21	(25)	(12)
1.23	Cash at end of quarter	28,068	28,068

<sup>+</sup> See chapter 19 for defined terms.

# Payments to Directors of the Entity and Associates of the Directors

# Payments to Related Entities of the Entity and Associates of the Related Entities

	00
1.24 Aggregate amount of payments to the parties included in item 1.2	194
1.25 Aggregate amount of loans to the parties included in item 1.11	-

1.26	Explanation n	ecessary for an	understanding	of the	transactions
------	---------------	-----------------	---------------	--------	--------------

	Directors'	fees and	consulting	fees at	normal	commercial	rates
--	------------	----------	------------	---------	--------	------------	-------

# **Non-Cash Financing and Investing Activities**

2.1	Details of financing and investing transactions which have had a material affect on consolidated Assets and liabilities but did not involve cash flows
2.2	Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

# **Financing Facilities Available**

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

		Amount Available \$A'000	Amount Used \$A'000
3.1	Loan facilities	1	-
3.2	Credit standby arrangements	-	-

<sup>+</sup> See chapter 19 for defined terms.

#### **Reconciliation of Cash**

(as s	onciliation of cash at the end of the quarter hown in the consolidated statement of cash flows) he related items in the accounts is as follows.	Current Quarter \$A'000	Previous Quarter \$A'000
4.1	Cash on hand and at bank	10,631	10,997
4.2	Deposits at call	392	3,669
4.3	Bank overdraft	1	-
4.4	Other (Term Deposit)	17,045	18,800
	Total: Cash at end of quarter (item 1.23)	28,068	33,466

# **Acquisitions and Disposals of Business Entities**

		Acquisitions	Disposals
		(Item 1.9(a))	(Item 1.10(a))
5.1	Name of entity	-	-
5.2	Place of incorporation or registration	-	-
5.3	Consideration for acquisition or disposal	-	-
5.4	Total net assets	-	-
5.5	Nature of business	-	-

## **Compliance Statement**

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign Here: Date: Wednesday 23rd January 2013

**Company Secretary** 

Print Name: Deanne Miller

#### **Notes**

- The quarterly report provides a basis for informing the market how the entity's
  activities have been financed for the past quarter and the effect on its cash position.
  An entity wanting to disclose additional information is encouraged to do so, in a note
  or notes attached to this report.
- 2. The definitions in, and provisions of, *AASB 1026: Statement of Cash Flows* apply to this report except for the paragraphs of the Standard set out below.
  - 6.2 reconciliation of cash flows arising from operating activities to operating profit or loss
  - 9.2 itemised disclosure relating to acquisitions
  - · 9.4 itemised disclosure relating to disposals
  - · 12.1(a) policy for classification of cash items
  - · 12.3 disclosure of restrictions on use of cash
  - · 13.1 comparative information
- 3. **Accounting Standards.** ASX will accept, for example, the use of International Accounting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.